| Literature DB >> 35205730 |
Dörte Wichmann1, Stefano Fusco2, Christoph R Werner2, Sabrina Voesch2, Benedikt Duckworth-Mothes1, Ulrich Schweizer1, Dietmar Stüker1, Alfred Königsrainer1, Karolin Thiel1, Markus Quante1.
Abstract
BACKGROUND: Esophageal cancer (EC) is the sixth-leading cause of cancer-related deaths in the world. Esophagectomy is the most effective treatment for patients without invasion of adjacent organs or distant metastasis. Complications and relevant problems may occur in the early post-operative course or in a delayed fashion. Here, innovative endoscopic techniques for the treatment of postsurgical problems were developed during the past 20 years.Entities:
Keywords: endoscopic complication management; esophageal cancer; postsurgical complication
Year: 2022 PMID: 35205730 PMCID: PMC8870330 DOI: 10.3390/cancers14040980
Source DB: PubMed Journal: Cancers (Basel) ISSN: 2072-6694 Impact factor: 6.639
Figure 1PRISMA 2020 flow diagram for the review process.
Figure 2A selection of instruments for endoscopic haemostasis (from left to right): APC lateral probe, OTSC, TTSC haemostasis clip, injection needle. With kind permission from Dr. J. Fundel and U. Schweizer.
Publications with more than five patients included with stent-based therapy in patients with AI after EC resections.
| Reference | Year | Study Type | Number of All Patients | Number of Patients after EC Resection | Success Rate in Patients | Mortality Rate |
|---|---|---|---|---|---|---|
| Roy-Choudhury et al. [ | 2001 | Case series | 14 | 14 | 92.86% | 7.14% |
| Hünerbein et al. [ | 2004 | Case series | 9 | 9 | 100% | 0% |
| Langer et al. [ | 2005 | Case series | 24 | 24 | n.n. | 25% |
| Schubert et al. [ | 2005 | Case series | 12 | 12 | 91.67% | 0% |
| Radecke et al. [ | 2006 | Case series | 9 | 5 | 66.67% | 44.44% |
| Han et al. [ | 2006 | Case series | 8 | 8 | 100% | 12.5% |
| Freeman et al. [ | 2007 | Case series | 21 | 21 | 95.24% | 4.76% |
| Kim et al. [ | 2008 | Case series | 17 | 7 | 76.47% | 5.88% |
| Tuebergen et al. [ | 2008 | Case series | 32 | 24 | 78.13% | 15.63% |
| Babor et al. [ | 2009 | Case series | 5 | 4 | 100% | 0% |
| Salminen et al. [ | 2009 | Case series | 10 | 2 | 80% | 50% |
| Van Heel et al. [ | 2010 | Case series | 33 | 1 | 69.69% | 21.21% |
| D’Cunha et al. [ | 2011 | Case series | 37 | 22 | 59.46% | 13.51% |
| Cerna et al. [ | 2011 | Case series | 5 | 4 | 80% | 0% |
| Schweigert et al. [ | 2011 | Case series | 22 | 22 | 77% | 23% |
| Smith et al. [ | 2020 | Case series | 11 | 11 | 90.9% | 9.1% |
| Total | 269 | 190 | 78.63% | 14.51% |
n.n. = not named.
Publications with more than five patients on ENPT in patients with AI after EC resections.
| Reference | Year | Study Type | Number of All Patients | Number of Patients after EC Resection | Success Rate in Patients after EC Resections | Mortality Rate |
|---|---|---|---|---|---|---|
| Weidenhagen et al. [ | 2010 | Case series | 6 | 6 | 100% | 16.67% |
| Brangewitz et al. [ | 2013 | Case series | 32 | 28 | n.n. | 15.62% |
| Schniewind et al. [ | 2013 | Case series | 17 | 14 | n.n | 11.76% |
| Schorsch et al. [ | 2014 | Case series | 35 | 21 | 95.24% | 5.17% |
| Mennigen et al. [ | 2015 | Case series | 22 | 19 | 86.36% | 13.64% |
| Möschler et al. [ | 2015 | Case series | 10 | 5 | 40% | n.n. |
| Kuehn et al. [ | 2016 | Case series | 21 | 11 | 81.82% | 4.76% |
| Laukötter et al. [ | 2017 | Case series | 52 | 39 | 89.74% | 9.61% |
| Mencio et al. [ | 2018 | Case series | 15 | 2 | 100% | 0% |
| Bludau et al. [ | 2018 | Case series | 77 | 51 | 80.39% | 11.69% |
| Pournaras et al. [ | 2018 | Prospective cohort study | 21 | 7 | 100% | 14.29% |
| Noh et al. [ | 2018 | Case series | 12 | 11 | 91.67% | 8.33% |
| Ooi et al. [ | 2018 | Case series | 10 | 3 | 66.67% | 30% |
| Valli et al. [ | 2018 | Case series | 12 | 7 | 71.42% | 0% |
| Min et al. [ | 2019 | Case series | 20 | 13 | n.n. | 5% |
| Leeds et al. [ | 2019 | Case series | 19 | 2 | 100% | 0% |
| Jeon et al. [ | 2020 | Case series | 22 | 22 | 86.36% | 0% |
| Jung et al. [ | 2021 | Case series | 30 | 23 | 87% | 6.67% |
| Zhang et al. [ | 2021 | Case series | 55 | 55 | 87.5% | 3.9% |
| Hayami et al. [ | 2021 | Case series | 23 | 23 | 82.6% | 13.04% |
| Total | 489 | 350 | 85.10% | 11.34% |
n.n.= not named.
Figure 3New combination device VACStent (Möller Medical GmbH, Fulda, Germany); the blue drain is connected to an electric vacuum pump. The device could be in place for 5 days.